Aptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to perform the upcoming phase 1 studies with Apta-1. By entering...
Read MoreAptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzzard Pharmaceuticals AB, Lipum AB, Thermo Fisher Scientific och Toleranzia AB. The newly established consortium aims to evaluate new treatments to...
Read MoreBioStock published an article on 9 March 2022 about Aptahem, which can be read in full below. Aptahem has communicated several positive news lately. Recently, the company received patent protection in Japan for patent family 2 regarding the drug...
Read MoreAptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 successfully has been prepared by the collaboration partner LGC Biotechnologies in the USA, according to timeplan. The GMP manufactured Apta-1 will be...
Read MoreVD kommenterar Det har blivit dags för ett nyhetsbrev från Aptahem med de senaste uppdateringarna kring vårt arbete med att ta vår läkemedelskandidat Apta-1 in i nästa utvecklingssteg för att utvärdera dess potential som en framtida behandling för sepsis...
Read MoreAptahem can today announce that in addition to previously reported positive preliminary data, the Toronto team has, from further studies, found essential positive effects in a Corona virus challenge induced Acute Lung Injury model with Apta-1 treatment. Studies show...
Read MoreAptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese Patent Office (JPO). With JPO’s approval of patent application 2020-519806, the protection of the company’s drug candidate Apta-1...
Read MoreBioStock published an article on 4 February 2022 about Aptahem, which can be read in full below. Aptahem has recently recruited to fill three key positions ahead of the phase I studies planned with sepsis candidate Apta-1. Karin Aschan...
Read MoreAptahem (publ) announces today that Thomas Rupp has been appointed CMC Director in the company. Thomas has worked with Aptahem for several year in the role as aptamer expert, but he will now also take on the role as...
Read MoreAptahem (publ) announces today that Maria Ekblad has been appointed new Chief Operating Officer (COO) in the company as of 14 January 2022. Maria has long and solid experience from the pharmaceutical industry where she has held senior management...
Read More